This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Biotech Stock Roundup: GILD's HIV Drug Approval, PRQR Surges on LLY Deal & More
by Zacks Equity Research
Updates from Gilead Sciences (GILD) and ProQR (PRQR) are the key highlights from the biotech sector during the past week.
Biotech: 3 Profitable Bios Worth Owning
by Andrew Rocco
The biotechnology space can be a difficult area to generate profits. Drugs take years to develop and often fail FDA approval. Today we will look at three top biotech stocks that are very profitable and have attractive future prospects.
Gilead (GILD) To Get Full Rights for Jounce's Immunotherapy
by Zacks Equity Research
Gilead Sciences (GILD) is set to buy the remaining rights to the potential first-in-class immunotherapy GS-181 from Jounce Therapeutics.
Zacks Industry Outlook Highlights Gilead Sciences, GSK, Immunocore and Syndax Pharmaceuticals
by Zacks Equity Research
Gilead Sciences, GSK, Immunocore and Syndax Pharmaceuticals are part of the Zacks Screen of the Week article.
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Gilead Sciences (GILD) closed at $85.01, marking a +0.31% move from the previous day.
4 Top Biotech Stocks Worth Adding to Your Portfolio in 2023
by Zacks Equity Research
New drug approvals and focus on coronavirus treatments should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position GILD, GSK, IMCR and SNDX well amid the volatility.
Gilead (GILD) Gets FDA Nod for Twice-Yearly HIV Treatment
by Zacks Equity Research
Gilead'ls (GILD) HIV franchise gets a boost with FDA's approval of twice-yearly HIV treatment Sunlenca for the treatment of HIV-1 infection in heavily treatment-experienced adults with multi-drug resistance.
Biotech is Set for a Blockbuster 2023: Here's Why
by Andrew Rocco
The biotech sector has been outperforming the major U.S. indices for the past few months. Can the strength continue?
Roche (RHHBY) Actemra Gets FDA Nod for Adults With COVID-19
by Zacks Equity Research
Roche (RHHBY) obtains FDA approval for Actemra (tocilizumab) intravenous (IV) for the treatment of COVID-19 in hospitalized adult patients. The drug was earlier granted an EUA.
Biotech Stock Roundup: MDGL Surges on NASH Data, TRDA, RCUS Down on Updates & More
by Ekta Bagri
Pipeline updates from Madrigal (MDGL) and Entrada (TRDA) are the key highlights from the biotech sector during the past week.
Merck (MRK), Seagen Keytruda-Padcev sBLAs Get FDA Priority Tag
by Zacks Equity Research
Merck (MRK) and Seagen's (SGEN) sBLAs seek approval of Padcev plus Keytruda for locally advanced or metastatic urothelial cancer in patients who are not eligible for cisplatin-containing chemotherapy.
Are Medical Stocks Lagging Gilead Sciences (GILD) This Year?
by Zacks Equity Research
Here is how Gilead Sciences (GILD) and HealthEquity (HQY) have performed compared to their sector so far this year.
Gilead Sciences (GILD) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $84.77 in the latest trading session, marking a -1.91% move from the prior day.
Entrada (TRDA) Down on Regulatory Update for DMD Candidate
by Zacks Equity Research
Entrada (TRDA) plunges on clinical hold notice from the FDA regarding its Investigational New Drug Application (IND) for Duchenne muscular dystrophy (DMD) candidate.
bluebird's (BLUE) SCD Studies Clinical Hold Lifted by the FDA
by Zacks Equity Research
bluebird (BLUE) announces that the partial clinical hold on studies evaluating lovo-cel for sickle cell disease (SCD) for patients under the age of 18 has now been lifted.
AstraZeneca (AZN) Gets EU Nod & CHMP Opinions for Some Drugs
by Zacks Equity Research
The CHMP recommends approvals for expanded use of AstraZeneca's (AZN) Enhertu in breast cancer, Imfinzi plus Imjudo in lung and liver cancers and Forxiga in heart failure.
Roche's (RHHBY) Hemophilia A Drug Gets Positive CHMP Opinion
by Zacks Equity Research
Roche (RHHBY) receives a positive CHMP recommendation for label expansion of the hemophilia A drug Hemlibra in the European Union (EU).
AbbVie (ABBV) Vraylar Gets FDA Nod for Major Depressive Disorder
by Zacks Equity Research
FDA approves AbbVie's (ABBV) Vraylar (cariprazine) for its fourth indication - the adjunctive treatment of patients with MDD.
BioCryst (BCRX) Down as it Discontinues Developing PNH Drug
by Zacks Equity Research
BioCryst (BCRX) down as it drops the development of BCX9930, which was being evaluated for PNH.
Cytokinetics (CYTK) Up Despite Unfavorable FDA Committee Voting
by Zacks Equity Research
Cytokinetics (CYTK) gets an unfavorable recommendation from CRDAC on omecamtiv mecarbil for the treatment of heart failure with reduced ejection fraction.
Top 5 High-Yield S&P 500 Stocks to Buy for 2023
by Rajani Lohia
With risks of elevated inflation, rising interest rates and geopolitical turmoil, investments in high-yield dividend stocks offer a defensive play. Stocks like GILD, CAG, CAT, CFG and NRG look attractive.
Gilead Sciences (GILD) Stock Moves -0.39%: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $88.40 in the latest trading session, marking a -0.39% move from the prior day.
Biotech Stock Roundup: HZNP Surges on AMGN Offer, TRDA Gains on VRTX Deal & More
by Zacks Equity Research
Acquisitions news from HZNP and AMGN form the key highlights from the biotech sector during the past week.
bluebird (BLUE) Up on Positive Data on Gene Therapies at ASH
by Zacks Equity Research
bluebird (BLUE) gains on positive data on Zyntgelo in beta-thalassemia and lovo-cel in sickle cell disease.
Gilead (GILD) Partners With Arcellx, ImmunoGen in Oncology
by Zacks Equity Research
Gilead (GILD) announces deals with Arcellx, Inc. and ImmunoGen to strengthen its oncology pipeline.